Antidepressants in Inflammatory Bowel Disease: A Systematic Review
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 7 of the 113 sources its claims cite were checked for support.
Abstract
BACKGROUND: Antidepressants are commonly used to treat symptoms of anxiety and depression in inflammatory bowel disease (IBD). Recent studies suggest a link between IBD activity and an individual's emotional state which raises the possibility that antidepressants may potentially modify the disease course of IBD. This systematic review thus primarily aims to evaluate the efficacy of antidepressants on IBD activity, and secondarily, on anxiety and depression. METHODS: MEDLINE, EMBASE, Cochrane (IBD Group), CINAHL, AMED, PsycINFO, and OpenGrey were searched from 1990 onward with no restrictions on study design. A quality appraisal was conducted using several scales as appropriate for each study design. A narrative synthesis was also conducted. RESULTS: Fifteen eligible studies included in the review (1 randomized controlled trial, 2 cohorts, 1 case-control, 1 cross-sectional survey, 1 qualitative, 2 audits, 1 case series, and 6 case reports) examined a range of antidepressants. Twelve studies suggested that antidepressants have a positive impact on IBD course. Nine studies reported anxiety and depression as an outcome, of these 8 reported beneficial effects of antidepressants. Most of the studies were deemed to be at low risk of bias, apart from the case reports, which were at high risk of bias. CONCLUSIONS: This research indicates that antidepressants may have a beneficial effect on IBD course. However, it is currently not possible to determine their efficacy for certain because of the lack of randomized trials. Further trials using objective measures of IBD activity, longer follow-up periods, and larger sample sizes are needed.
Overview
CoChat Summary
## TL;DR
This systematic review found that antidepressants are commonly used in IBD and that 12 of 15 included studies suggested a positive impact on IBD course, but the authors conclude that efficacy cannot be determined for certain because the evidence is mostly observational. Evidence for anxiety/depression outcomes was also generally favorable, with 8 of 9 studies reporting benefit.
## Key findings
- The review included 15 studies: 1 placebo-controlled RCT, 2 cohorts, 1 case-control study, 1 cross-sectional survey, 1 qualitative study, 2 audits, 1 case-series, and 6 case reports.
- 12 studies suggested antidepressants had a positive impact on IBD course; 9 studies reported anxiety/depression as an outcome, and 8 of these reported beneficial effects.
- In the RCT, 44 participants were randomized to duloxetine 60 mg daily or placebo for 12 weeks; symptom severity improved in the intervention group (P = 0.02), and depression/anxiety also improved (P = 0.041 and P = 0.049).
- In the retrospective case-control study, the antidepressant group had fewer relapses and steroid courses after starting antidepressants than before (relapses P = 0.002; steroids P < 0.001), and relapses differed significantly vs controls (P = 0.03).
- In the cross-sectional survey of 98 participants, 79% reported perceived improvements, 67% reported no change in perceived disease activity, 25% reported disease activity improvement, and 87% reported improved psychological well-being.
## Methods
- Systematic review of antidepressants in human IBD, with no restriction on study design; searches were run in MEDLINE, EMBASE, Cochrane IBD Group, CINAHL, AMED, PsycINFO, and Open Grey from 1990 onwards.
- Included studies had to involve clinically diagnosed IBD and an antidepressant exposure (tricyclics, MAOIs, SSRIs, SNRIs, or atypical antidepressants), with outcomes on IBD remission/activity or anxiety/depression.
- The authors conducted quality appraisal using design-appropriate tools and used a narrative synthesis; a meta-analysis was planned but not done because of heterogeneity in study design and outcomes.
## Limitations
- The paper states that most included studies were observational, uncontrolled, and non-randomised, so “no firm conclusions” can be drawn about efficacy; the review also notes only one RCT and six case reports among the 15 studies.
- The authors state that many studies had small sample sizes, single-source sampling, and short follow-up; only 3 studies had follow-up of 2 years or more, while 5 had follow-up of 12 weeks or less.
- Evident from the text: the review included only English-language papers for practical reasons, and one author conducted screening/data extraction; the text explicitly identifies these as limitations of the review.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 2 Not valid · 101 Not checked · 30 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The study was given an overall quality rating of 'Good' indicating a low risk of bias.”
What the sources say
- Could not verifycites [15] 15. Mikocka-Walus A, Andrews JM. Attitudes towards antidepressants among people living with inflammatory bowel disease: an online Australia-wide survey. Journal of Crohn's & colitis. 2014;8(4):296-303. sourceExperimental — accuracy not yet measured
The Methods describe a retrospective chart review, and the Discussion explicitly calls the design retrospective, rather than a cross-sectional survey. Our copy gives no overall quality rating of “Good” or assessment of low risk of bias; searches for those terms found no supporting passage. Such a rating may have been assigned by the citing authors, but it cannot be verified from this source. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Eighty-three per cent of UC patients had at least a moderate symptomatic improvement on TCA, compared with 50% of CD patients ( P = 0.01).”
What the sources say
- Supportedcites [19] 19. Iskandar HN, Cassell B, Kanuri N, Gyawali CP, Gutierrez A, Dassopoulos T, et al. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. Journal of Clinical Gastroenterology. 2014;48(5):423-9. source
The Results section states that, at the first follow-up visit, 83% of UC patients had at least moderate symptomatic improvement on TCA, compared with 50% of CD patients (P = 0.01). The Discussion identifies the study design as retrospective. (LLM, conf=0.95)
plainstates an associationn = 81 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Antidepressant treatment was not associated with a significant improvement in CDAI compared to the control group (mean improvement -62.9 (SD 99.5), P = 0.57)”
What the sources say
- Partly supportedcites [20] 20. Yanartas O, Kani HT, Bicakci E, Kilic I, Banzragch M, Acikel C, et al. The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease. Neuropsychiatric Disease and Treatment. 2016;12:673-83. sourceExperimental — accuracy not yet measured
The Results section 'Comparison of variation in each parameter between baseline and final visit (between groups A and B)' confirms the qualitative core of the claim: for CDAI (and MMS, CRP, WBC, hemoglobin, hematocrit, MCV) the mean change between baseline and final visit was statistically insignificant when groups were compared. However, our copy nowhere states the numbers the claim attributes (-62.9, SD 99.5, P = 0.57); those would sit in Table 4, whose cell values are not present in the text we hold, so the magnitude and P-value cannot be verified. Our copy also frames the comparator differently: group B was the 20 patients who were nonadherent to the offered psychiatric drug treatment, not a control group, and within group A the CDAI improved significantly from baseline (Abstract Results; Results 'within groups A and B'; Discussion and Conclusion state 'Psychiatric drug treatment was found to be associated with an improvement in CDAI'). (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Yanartas et al. (2016) was at low risk of bias”
What the sources say
- Could not verifycites [20] 20. Yanartas O, Kani HT, Bicakci E, Kilic I, Banzragch M, Acikel C, et al. The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease. Neuropsychiatric Disease and Treatment. 2016;12:673-83. sourceExperimental — accuracy not yet measured
The Patients and methods section describes the study design, and the Discussion’s Limitations section identifies several limitations, but neither assesses the study as being at low risk of bias. A search for risk-of-bias and quality-assessment language found no such judgment in our copy. (LLM, conf=0.75)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“AD treatment was found to be associated with an improvement in CDAI in patients with IBD. Intervention: 197.41 (130.60) to 101.08 (65.88) (p=0.011); Control: 58.50 (74.94) to 83.50 (62.68) (p=0.710).”
What the sources say
- Partly supportedcites Yanartas (2016) sourceExperimental — accuracy not yet measured
The Results section reports a statistically significant improvement in CDAI after six months among patients who adhered to psychiatric drug treatment, supporting the central claim. Our copy does not provide the quoted p=0.011 or baseline and follow-up values, so those figures cannot be verified. The Methods specify that CDAI measures Crohn’s disease activity, not activity across all IBD patients. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
50 more claims · 1 with their cited sources checked
Create a free account to see all 138 claims and to verify the 98 references still open.
- Probably not a substantial claim. 58
- The quote only partly states this claim. 3
- It may state two separate claims as one. 45
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of psychotherapy, namely cognitive behavioural therapy, psychodynamic therapy, acceptance and commitment therapy, stress management programs, mindfulness, hypnosis, antidepressant medication and regular physical activity, leads to an improvement in the patient's quality of life.”
From PSYCHO-EMOTIONAL STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Крім того, під час вивчення оцінювали рівень кортизолу у волоссі: з'ясувалося, що концентрація кортизолу корелювала з тривогою на вихідному рівні, але істотно не змінилася в групі ACT за період дослідження у порівнянні з контрольною групою [62].”
From PSYCHO-EMOTIONAL STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“ACT була викликана зниженням сприйманого стресу і депресії, але не тривогою, у порівнянні з контрольними особами.”
From PSYCHO-EMOTIONAL STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“Moreover, desipramine and fluoxetine reduce the risk of colitis in animal models, even though these data have to be confirmed in clinical trials [46].”
From Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications (2021) · cites this paper as [46]
In the citing paper
“Unfortunately, the evidence to date for any benefit of gut-brain neuromodulators[42] or psychological therapies[43], including cognitive behavioural therapy, gut-directed hypnotherapy, and mindfulness as an adjunct to conventional treatment in IBD is inconclusive, largely due to the fact that these have been tested in unselected patients.”
From Bidirectional brain-gut axis effects influence mood and prognosis in IBD: A systematic review and meta-analysis (2022) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“2 (0.01%) had active disease”
Reported 0.01 · recomputed 3.921569
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
The burden of inflammatory bowel disease in Europe
Burisch, J., Jess, T., Martinato, M., & Lakatos, P. L. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.01.010 · Cited by 961
Ford, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M. M., & Moayyedi, P. (2009) · Gut · doi:10.1136/gut.2008.163162 · Cited by 582
Mikocka-Walus, A., Knowles, S. R., Keefer, L., & Graff, L. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000620 · Cited by 567
Self-citationFord, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.148 · Cited by 405
Tynan, R. J., Weidenhofer, J., Hinwood, M., Cairns, M. J., Day, T. A., & Walker, F. R. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.12.011 · Cited by 386
Interleukin‐6 Serum Levels in Depressed Patients before and after Treatment with Fluoxetine
SŁUŻEWSKA, A., RYBAKOWSKI, J. K., LACIAK, M., MACKIEWICZ, A., SOBIESKA, M., & WIKTOROWICV, K. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb32372.x · Cited by 306
Fuller-Thomson, E., & Sulman, J. (2006) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200608000-00005 · Cited by 292
Antidepressant therapy and C-reactive protein levels
O'Brien, S. M., Scott, L. V., & Dinan, T. G. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.011015 · Cited by 148
Walker, E. A., Gelfand, M. D., Gelfand, A. N., Creed, F., & Katon, W. J. (1996) · General Hospital Psychiatry · doi:10.1016/0163-8343(96)00036-9 · Cited by 144
Research works printed but not linked: 4
- Mikocka-Walus, 2009, Eur Gastroeneterol and Hepatol Rev, 5, 1
- Ramos Rivers, 2014, Gastroenterology, 1, S
- Kahn, 2014, J Gen Intern Med, 29, S348
- Fuller-Thomson, 2006, Inflamm Bowel Dis, 12, 697, 10.1097/00054725-200608000-00005 · DOI · Paper page
Cited by
Bi-directionality of brain–gut interactions in patients with inflammatory bowel disease
Gracie, D. J., Guthrie, E. A., Hamlin, P. J., & Ford, A. C. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.027 · Cited by 408
Gracie, D. J., Hamlin, P. J., & Ford, A. C. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30089-5 · Cited by 354
Gut liver brain axis in diseases: the implications for therapeutic interventions
Yan, M., Man, S., Sun, B., Ma, L., Guo, L., Huang, L., & Gao, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01673-4 · Cited by 287
Frolkis, A. D., Vallerand, I. A., Shaheen, A.-A., Lowerison, M. W., Swain, M. G., Barnabe, C., Patten, S. B., & Kaplan, G. G. (2019) · Gut · doi:10.1136/gutjnl-2018-317182 · Cited by 228
Fairbrass, K. M., Lovatt, J., Barberio, B., Yuan, Y., Gracie, D. J., & Ford, A. C. (2022) · Gut · doi:10.1136/gutjnl-2021-325985 · Cited by 225
Metadata
- Authors
- Macer, B. J. D., Prady, S. L., & Mikocka-Walus, A.
- Affiliations
- Deakin University (AU)
- University of York (GB)
- ORCID
- Prady, Stephanie L.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-04
- Volume
- 23
- Issue
- 4
- Pages
- 534-550
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2592131189
- Cited by
- 92
- References
- 29
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 12 · 2023: 8 · 2022: 15 · 2021: 17 · 2020: 9 · 2019: 9 · 2018: 7 · 2017: 5
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- green
- orcid.org
- Locations
- Inflammatory Bowel Diseases (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Figshare (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- antidepressants, inflammatory bowel disease
- MeSH terms
- Antidepressive Agents, Anxiety, Depression, Humans, Inflammatory Bowel Diseases, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidepressants in Inflammatory Bowel Disease: A Systematic Review. https://app.cochat.ai/papers/10.1097/mib.0000000000001059
- The paper
- Macer, B. J. D., Prady, S. L., & Mikocka-Walus, A. (2017). Antidepressants in Inflammatory Bowel Disease: A Systematic Review. Inflammatory Bowel Diseases. https://doi.org/10.1097/mib.0000000000001059
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.